 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Drug:
|
GSK189254
|
|
Clinical Trial ID:
|
NCT00387413
|
|
Mode of action:
|
H3 antagonist
|
|
Phase:
|
Discontinued
|
|
Company:
|
GlaxoSmithKline
|
|
Note:
|
First indication for narcolepsy; possibly addresses
cognitive deficit in schizophrenia
|
Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K,
Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis
JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J,
Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN,
Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts
JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N,
Wadsworth G, Wald JA, White T, Witherington J, Woolley ML,
Worby A, Wilson DM. GSK189254, a novel H3 receptor
antagonist that binds to histamine H3 receptors in
Alzheimer's disease brain and improves cognitive performance
in preclinical models. J Pharmacol Exp Ther. 2007
Jun;321(3):1032-45. Abstract
Ito C. The role of the central histaminergic system on
schizophrenia. Drug News Perspect . 2004 Jul-Aug ;
17(6):383-7. Abstract
|
|
|
|
|
Text Size 
See our most recent Schizophrenia Bulletin theme Webinar: